clinical-trials

Aclerastide: Effective Therapy for Diabetic Foot Ulcers

Aclerastide, an analog of angiotensin 1-7, shows strong potential in treating diabetic foot ulcers through progenitor proliferation, vascularization, collagen deposition, and re-epithelialization. Preclinical studies demonstrate its superiority over existing topical growth factors, with Phase II trials confirming faster wound closure lasting up to 20 weeks. Phase III trials are now recruiting patients.